Atsena Therapeutics is a clinical-stage gene therapy company focused on reversing or preventing blindness from inherited retinal diseases using novel AAV-based genetic medicine. Its pipeline includes programs such as ATSN-201 for X-linked retinoschisis and ATSN-101 for GUCY2D-associated Leber congenital amaurosis, both in Phase I/II trials and designed to address conditions with no approved treatments. Atsena’s proprietary gene delivery platform is engineered to improve delivery to retinal cells and enable durable therapeutic expression, with ongoing efforts to advance pivotal studies and bring transformative therapies to patients with vision loss.